军事知识服务平台
诱导型斑马鱼骨质疏松模型的构建及其在抗骨质疏松药物筛选中的应用
Construction of an induced zebrafish osteoporosis model and its application in antiosteoporosis drug screening
摘要 目的 建立并验证一种新型的斑马鱼骨质疏松模型,并将其应用于筛选海洋天然产物中的抗骨质疏松先导化合物.方法 通过柠檬酸铁铵(ferric ammonium citrate,FAC)处理,破坏骨代谢平衡,建立斑马鱼骨质疏松模型;通过茜素红染色与钙黄绿素处理检测颅骨组织完整性;通过定量分析茜素红染色强度,评估骨质疏松表型严重程度及候选化合物的治疗效果.结果 FAC处理后,斑马鱼硬骨转化和钙盐沉积相关基因sox9b与bgp的表达水平下降;角舌骨(ch)和舌骨下领弓(hm)发生部分或完全缺失;颅骨经茜素红染色后着色较浅,经钙黄绿素处理后荧光较微弱.在所有候选化合物处理条件下,上述骨质疏松表型均未得到有效改善.结论 FAC处理能引起成骨过程中的硬骨沉积异常,导致颅骨结构缺失以及骨密度下降.利用该骨质疏松模型能实现对候选化合物快速且有效的筛选,然而在本阶段筛选中,所有候选化合物均未表现出显著的抗骨质疏松药效.
Abstract:
Objective While the pathological and physiological basis of osteoporosis has been systematically understood and recognized in humans,the development of related drugs remains at its early stages.This study aims to establish and validate a novel zebrafish osteoporosis model and apply it to screen marine natural products for potential antiosteoporosis lead compounds.Methods An osteoporosis model was established in zebrafish by disrupting bone metabolic balance through treatment with ferric ammonium citrate(FAC).Alizarin red staining and calcein treatment were performed to assess cranial bone integrity.The severity of the osteoporotic phenotype and the therapeutic effects of candidate compounds were evaluated by quantitatively analyzing the intensity of Alizarin red staining.Results Following FAC treatment,the expression levels of genes related to osteogenesis and calcium salt deposition,sox9b and bgp,were decreased.Partial or complete bone loss was observed in the ceratohyal(ch)and hypomandibular(hm)bones.Cranial bones exhibited lighter staining with alizarin red and weaker fluorescence after Calcein treatment.Under all candidate compound treatment conditions,the aforementioned osteoporotic phenotypes showed no significant improvement.Conclusion FAC treatment can induce abnormalities in bone mineralization during osteogenesis,leading to structural defects in cranial bones and decreased bone density.This osteoporosis model enables rapid and efficient screening of candidate compounds;however,at the current screening stage,none of the candidate compounds exhibits significant anti-osteoporotic efficacy.
刊 名 中国海洋药物 ISTIC
年,卷(期): 2026, 45(2)
分类号: R931.77
机标分类号: R965.1 R683 R782.14
在线出版日期: 2026年6月3日
基金项目: 2018YFA0801000:国家重点研发计划ZR2021MC075:山东省自然科学基金面上项目WLSP202103:武陵山区特色资源植物种质保护与利用湖北省重点实验室开放课题,